Drugs / JMT108
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07317505 | Dec 2025 → Jul 2029 expected | cancer | Conjupro Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07280832 | Dec 2025 → Nov 2026 expected | CDK4 linked melanoma | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06877650 | Apr 2025 → Mar 2028 expected | cancer | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMT108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07317505 ↗ |
| Route | Intravenous | “Intravenous (IV) administration” NCT07280832 ↗ |